GlassScriptPhysician profile
Hyman D Lipsitz
NPI 1740257567
$1,078.35
in general payments reported to CMS, 2019-2025
10 companies · $25.45 in 2025
The $25.45 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.34 · 2021: $11.15 · 2022: $251 · 2023: $528 · 2024: $185 · 2025: $25.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711 · Travel and Lodging: $28.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.12 |
| Travel and Lodging | $28.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $351.35 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $326.21 | 2022-2025 | Entyvio |
| Olympus America INC. | $108.67 | 2023 | Endoclot Phs, Endoclot Sis |
| Janssen Biotech, INC. | $66.43 | 2021-2022 | |
| Genzyme Corporation | $63.28 | 2023-2024 | |
| Celgene Corporation | $49.78 | 2022-2023 | Zeposia |
| Pfizer INC. | $47.67 | 2019-2023 | |
| Ethicon US, LLC | $37.50 | 2019 | |
| Qol Medical, LLC | $15.62 | 2019 | |
| Boston Scientific Corporation | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hyman Lipsitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.